SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx’s multiplexed PlexPCR® and ResistancePlus® molecular diagnostic tests across the region.
The agreement provides Serosep customers with access to SpeeDx’s proprietary technology for infectious disease diagnostics, in line with Serosep’s goal of improving lives while supporting the everyday struggles faced by laboratories. The SpeeDx portfolio includes the market-leading ResistancePlus MG assay – for simultaneous detection of Mycoplasma genitalium and genetic markers for azithromycin resistance – as well as a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further ResistancePlus assays will be released later this year – including a test for gonorrhea – along with a comprehensive PlexPCR multiplex panel for respiratory virus testing.
“There’s an obvious synergy between SpeeDx and Serosep, and we share the common goal of offering innovative solutions to our customers,” said Colin Denver, CEO of SpeeDx. “This strategic distribution agreement will extend our reach in Europe as we continue to expand our test portfolio.”